Visus Therapeutics announced it has entered into a worldwide exclusive licensing agreement with Cella Therapeutics to develop an array of investigational ophthalmic therapies to treat glaucoma and age-related macular degeneration (AMD). The company also announced a worldwide exclusive licensing agreement with DelSiTech, a provider of biodegradable, silica-based, controlled-release materials, to develop novel drug delivery technology that can help optimize the clinical …
Aequus, reVision to collaborate on Stargardt disease treatment
Aequus Pharmaceuticals and reVision Therapeutics will collaborate to develop a treatment for Stargardt disease, according to a press release.In addition, the agreement grants Aequus the option to acquire the North American commercial rights to REV-0100 from reVision.
Gene therapy start-up Vedere Bio II launches to treat blindness
The company, Vedere Bio II, launched with $77 million in series A financing to develop what it calls a “mutation agnostic optogenetics technology” to restore vision. As its name suggests, Vedere Bio II is a sequel to its predecessor company, Vedere Bio, which Novartis quietly acquired last year in a deal worth up to $280 million.
AI-based eye test could help prevent severe vision loss
Researchers from Imperial College London and University College London (UCL) carried out a clinical trial using retinal imaging technology known as Detection of Apoptosis in Retinal Cells (DARC). When tested on 113 patients in the trial, the technology was able to identify areas of the eye that were showing signs of geographic atrophy (GA) – a common condition that causes …
Novartis Announces Positive Results From Phase 3 Trials of Beovu in DME, Including Dosing Intervals Up to 16 Weeks
Novartis announced positive results from two phase 3 clinical trials assessing Beovu (brolucizumab) 6 mg versus aflibercept 2 mg in patients with diabetic macular edema (DME). Year 2 of the pivotal KITE trial evaluated Beovu on up to 16-week dosing intervals, and the 1-year KINGFISHER study evaluated Beovu dosed every 4 weeks.1,3 Both trials demonstrated an overall well-tolerated safety profile.
Oxurion Announces Publication of Positive Phase 1 Clinical Data Evaluating THR-687 for Treatment of DME
Oxurion announced that the positive phase 1 study of THR-687, a novel, highly potent integrin agonist for the treatment of DME has just been published in Ophthalmology Science. The multicenter, dose escalation study was designed to evaluate the safety and preliminary efficacy of three dose levels of THR-687 (0.4, 1.0 or 2.5mg) in subjects with center-involved DME following a single intravitreal …
Berlin’s Dopavision raises €12M to halt myopia progression in children and adolescents; here’s how
Dopavision is a Berlin-based company developing digital therapeutics for myopia. Nearsightedness (myopia) is a vision condition in which patients can see objects near to them clearly, but objects farther away are blurry.Dopavision raises Series A roundIn a recent development, the company announced that it has raised €12M in its Series A round of funding. The round was led by Seventure …
Omni surgical system reduces IOP, medication use
The Omni surgical system reduced IOP through 3 months in patients with open-angle glaucoma, according to research presented at the American Society of Cataract and Refractive Surgery meeting. Brian Flowers, MD, presented 3-month interim data from the ORION study exploring the efficacy and safety of the Omni surgical system (Sight Sciences) in pseudophakic eyes with mild to moderate open-angle glaucoma. Patients …
Spatial technology measures association between green space exposure, myopia
Using satellite imaging techniques, researchers were able to establish an association between green space exposure at school and the change in school-specific myopia prevalence. Even a relatively small increase in green space exposure was associated with a nearly 30% lesser risk for non-myopic children to develop myopia.
Robotic scanner automates diagnostic imaging in the eye
Engineers and ophthalmologists at Duke University have developed a robotic imaging tool that can automatically detect and scan a patient’s eyes for markers of different eye diseases. The new tool, which combines an imaging scanner with a robotic arm, can automatically track and image a patient’s eyes in less than a minute, and produce images that are as clear as …
